Physician profile
Richard I Sultan
NPI 1295700359
$4,585.22
in general payments reported to CMS, 2019-2025
34 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,677 · 2020: $484 · 2021: $438 · 2022: $399 · 2023: $754 · 2024: $364 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,836.04 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Neurelis, INC. | $626.68 | 2021-2025 | Valtoco |
| Biogen, INC. | $339.56 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $273.20 | 2019-2021 | |
| Rhodes Pharmaceuticals L.P. | $267.27 | 2019 | |
| Emd Serono, INC. | $229.22 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $165.28 | 2019 | |
| Tris Pharma INC | $83.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $68.04 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $66.00 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $55.23 | 2019 | |
| Ironshore Pharmaceuticals INC. | $47.07 | 2019-2020 | |
| Greenwich Biosciences, INC. | $45.24 | 2019 | |
| Tanabe Pharma America, INC. | $43.63 | 2020-2022 | |
| Eisai INC. | $39.03 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $31.18 | 2024 | Varithena Administration Pack |
| Strongbridge US INC. | $30.71 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $30.69 | 2020 | |
| Amneal Pharmaceuticals LLC | $29.45 | 2019-2023 | Lyvispah |
| Takeda Pharmaceuticals U.S.A., INC. | $28.79 | 2019-2020 | |
| Genentech USA, INC. | $27.92 | 2019 | |
| Grifols USA, LLC | $26.83 | 2019 | |
| Lilly USA, LLC | $26.14 | 2019 | |
| Upsher-Smith Laboratories LLC | $22.97 | 2019 | |
| Fisher & Paykel Healthcare INC | $18.75 | 2025 | Fisher & Paykel Healthcare |
| Alnylam Pharmaceuticals INC. | $15.68 | 2019 | |
| Adamas Pharmaceuticals, INC. | $15.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.78 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.43 | 2019 | |
| Philips North America LLC | $14.40 | 2019 | |
| Lundbeck LLC | $13.80 | 2019 | |
| Bausch Health US, LLC | $13.68 | 2019 | |
| Sk Life Science, INC. | $12.40 | 2020 | |
| Mallinckrodt Enterprises LLC | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Sultan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.